Radiopharm Theranostics Limited ( (AU:RAD) ) has shared an update.
Radiopharm Theranostics Limited has announced positive data from studies on its RAD202 product, presented at the European Molecular Imaging Meeting 2025. The data highlights the specific tumor targeting and favorable biodistribution of 68Ga-RAD202 for imaging, and the efficacy of 177Lu-RAD202 in reducing tumor volume and extending survival in HER2-positive solid tumors. These findings support ongoing clinical trials and suggest potential benefits for patients with advanced HER2-positive cancers, positioning the company as a leader in addressing unmet needs in oncology.
More about Radiopharm Theranostics Limited
Radiopharm Theranostics Limited is a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals. The company is listed on the ASX and has a pipeline of six distinct platform technologies for cancer diagnostics and therapeutics, including peptides, small molecules, and monoclonal antibodies, in various stages of development.
YTD Price Performance: 16.67%
Average Trading Volume: 9,506,150
Technical Sentiment Consensus Rating: Hold
Current Market Cap: A$65.35M
For a thorough assessment of RAD stock, go to TipRanks’ Stock Analysis page.